A5086220270- Health Systems, Economic Evaluations, Quality of Life
- Economic and Financial Impacts of Cancer
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Palliative Care and End-of-Life Issues
- HER2/EGFR in Cancer Research
- Health and Medical Studies
- Advanced Breast Cancer Therapies
- Childhood Cancer Survivors' Quality of Life
- Healthcare Policy and Management
- Lung Cancer Diagnosis and Treatment
- Complementary and Alternative Medicine Studies
- Cancer survivorship and care
- Gastric Cancer Management and Outcomes
- Clinical practice guidelines implementation
- Global Health Care Issues
- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- Healthcare cost, quality, practices
- Melanoma and MAPK Pathways
- Breast Cancer Treatment Studies
- Radiopharmaceutical Chemistry and Applications
- Biosimilars and Bioanalytical Methods
- Lung Cancer Research Studies
University of Basel
2009-2023
Federal Office of Public Health
2020
Swiss Group For Clinical Cancer Research
2008-2018
University of Bern
1996-2007
Adding bevacizumab to chemotherapy improves response rates and progression-free survival (PFS) in metastatic breast cancer (mBC). We aimed demonstrate decreased toxicity with metronomic chemotherapy/bevacizumab compared paclitaxel/bevacizumab. This multicenter, randomized phase III trial either paclitaxel (arm A) or daily oral capecitabine-cyclophosphamide B) as first-line treatment patients HER2-negative advanced cancer. The primary endpoint was the incidence of selected grade 3–5 adverse...
Background/Aim. Cancer, one of the leading causes mortality in world, imposes a substantial economic burden on each society, including Serbia. The aim this study was to evaluate major cancer cost drivers Methods. A retrospective, indepth, bottom-up analysis two combined databases performed order quantify relevant costs. End-of-life data were obtained from patients with cancer, who deceased within first year established diagnose, basic demographics, diagnosis, tumour histology, medical...
3503 Background: Chemotherapy plus bevacizumab is a standard option for first-line treatment in metastatic colorectal cancer patients. We assessed whether no continuation non-inferior to of after stop chemotherapy. Methods: In an open-label, phase 3 multicenter study conducted Switzerland, patients with unresectable having non-progressive disease 4-6 months chemotherapy were randomly assigned 1:1 ratio continuing (7.5 mg/kg every weeks) or treatment. CT scans done 6 weeks between...
Journal Article A cost‐effectiveness analysis of trametinib plus dabrafenib as first‐line therapy for metastatic BRAF V600‐mutated melanoma in the Swiss setting Get access K. Matter‐Walstra, Matter‐Walstra Institute Pharmaceutical Medicine (ECPM) University Basel Klingelbergstraße 61 CH‐4056 SwitzerlandSAKK Coordinating Centre Bern Switzerland Correspondence Klazien Matter‐Walstra. E‐mail: klazien.matter@unibas.ch Search other works by this author on: Oxford Academic Google Scholar R. Braun,...
The use of cancer related therapy in patients at the end-of-life has increased over time many countries. Given a lack published Swiss data, objective this study was to describe delivery health care during last month before death patients. Claims data were used assess utilization (identified by registry four participating cantons), deceased between 2006-2008. Primary endpoints hospitalization rate and therapies 30 days death. Multivariate logistic regression assessed explanatory value patient...
Adding cetuximab to standard chemotherapy results in a moderate increase of overall survival patients with advanced non-small-cell lung cancer (NSCLC), but the cost-effectiveness is unknown.A Markov model was constructed based on First-Line ErbituX randomized trial, adding cisplatin-vinorelbine first-line NSCLC. The primary outcome incremental ratio (ICER) cetuximab, expressed as cost per quality-adjusted life year (QALY) gained, and relative willingness-to-pay threshold €60 000/QALY. impact...
The use of cancer-related therapies in cancer patients hospitalized at the end life has increased many countries over time. Given scarcity published Swiss data, objective this study was to evaluate influence hospital type and other factors on delivery health care during last month before death. Claims data were used assess utilization (identified by registry four participating cantons) who deceased between 2006 2008. Primary endpoints 30 days Multivariate logistic regression assessed...
Abstract Background Climate- or holiday-related seasonality in hospital admission rates is well known for many diseases. However, little research has addressed the impact of tourism on rates. We therefore investigated influence emergency Switzerland, where winter and summer leisure sport activities large mountain regions can generate orthopedic injuries. Methods Using small area analysis, service areas (HSAo) were evaluated Winter defined using guest bed accommodation rate patterns houses...
Number of days spent in acute hospitals (DAH) at the end life is regarded as an important care quality indicator for cancer patients. We analysed DAH during 90 prior to death patients from four Swiss cantons. Claims data insurance provider with about 20% market share and patient record review identified 2086 dying cancer. calculated total per patient. Multivariable generalised linear modelling served evaluate potential explanatory variables. Mean was 26 days. In multivariable model, using...